Evidence map›Paper›PMID 30689661›Full record

ArticlePloS one2019

Lapachol and synthetic derivatives: in vitro and in vivo activities against Bothrops snake venoms.

Marcelo A Strauch, Marcelo Amorim Tomaz, Marcos Monteiro-Machado, Bruno Lemos Cons, Fernando Chagas Patrão-Neto, Jhonatha da Mota Teixeira-Cruz, Matheus da Silva Tavares-Henriques, Pâmella Dourila Nogueira-Souza, Sara L S Gomes, Paulo R R Costa and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Crystal structure and Hirshfeld surface analysis of lapachol acetate 80 years after its first synthesis.Acta crystallographica. Section E, Crystallographic communications · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Marcelo A StrauchLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Marcelo Amorim TomazLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.ORCID 0000-0002-6769-7899
Marcos Monteiro-MachadoLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Bruno Lemos ConsLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Fernando Chagas Patrão-NetoLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.ORCID 0000-0002-4583-0476
Jhonatha da Mota Teixeira-CruzLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.ORCID 0000-0002-3167-0723
Matheus da Silva Tavares-HenriquesLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Pâmella Dourila Nogueira-SouzaLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Sara L S GomesLaboratório de Química Bioorgânica, Instituto de Pesquisas de Produtos Naturais Walter Mors-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Paulo R R CostaLaboratório de Catálise Orgânica, Instituto de Pesquisas de Produtos Naturais Walter Mors-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Edgar SchaefferLaboratório de Química Bioorgânica, Instituto de Pesquisas de Produtos Naturais Walter Mors-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Alcides J M da SilvaLaboratório de Química Bioorgânica, Instituto de Pesquisas de Produtos Naturais Walter Mors-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Paulo A MeloLaboratório de Farmacologia das Toxinas, Instituto de Ciências Biomédicas-Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ, Brazil.
Universidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is known that local tissue injuries incurred by snakebites are quickly instilled causing extensive, irreversible, tissue destruction that may include loss of limb function or even amputation. Such injuries are not completely neutralized by the available antivenins, which in general are focused on halting systemic effects. Therefore it is prudent to investigate the potential antiophidic effects of natural and synthetic compounds, perhaps combining them with serum therapy, to potentially attenuate or eliminate the adverse local and systemic effects of snake venom. This study assessed a group of quinones that are widely distributed in nature and constitute an important class of natural products that exhibit a range of biological activities. Of these quinones, lapachol is one of the most important compounds, having been first isolated in 1882 from the bark of Tabebuia avellanedae. METHODOLOGY/PRINCIPAL

findingsIt was investigated the ability of lapachol and some new potential active analogues based on the 2-hydroxi-naphthoquinone scaffold to antagonize important activities of Bothrops venoms (Bothrops atrox and Bothrops jararaca) under different experimental protocols in vitro and in vivo. The bioassays used to test the compounds were: procoagulant, phospholipase A2, collagenase and proteolytic activities in vitro, venom-induced hemorrhage, edematogenic, and myotoxic effects in mice. Proteolytic and collagenase activities of Bothrops atrox venom were shown to be inhibited by lapachol and its analogues 3a, 3b, 3c, 3e. The inhibition of these enzymatic activities might help to explain the effects of the analogue 3a in vivo, which decreased skin hemorrhage induced by Bothrops venom. Lapachol and the synthetic analogues 3a and 3b did not inhibit the myotoxic activity induced by Bothrops atrox venom. The negative protective effect of these compounds against the myotoxicity can be partially explained by their lack of ability to effectively inhibit phospholipase A2 venom activity. Bothrops atrox venom also induced edema, which was significantly reduced by the analogue 3a.

conclusionsThis research using a natural quinone and some related synthetic quinone compounds has shown that they exhibit antivenom activity; especially the compound 3a. The data from 3a showed a decrease in inflammatory venom effects, presumably those that are metalloproteinase-derived. Its ability to counteract such snake venom activities contributes to the search for improving the management of venomous snakebites.

Indexed as

AnimalsBlood CoagulationBothropsCollagenasesMiceNaphthoquinonesNeurotoxinsPhospholipases A2Snake VenomsCollagenaseslapacholNaphthoquinonesNeurotoxinsPhospholipases A2Snake Venoms

Identifiers

PMID30689661
PMCPMC6349327
OpenAlexW2912725805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.